Norditropin Flexpro (Somatropin)

Somatropin, the active ingredient in Norditropin Flexpro, is a human growth hormone presented as a sterile solution for injection for subcutaneous use. It replaces deficient endogenous growth hormone and supports normal growth and metabolism in patients with growth hormone deficiency, Turner syndrome, Prader‑Willi syndrome, chronic renal insufficiency, and idiopathic short stature.

GNH USA supplies Norditropin Flexpro as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Norditropin Flexpro (somatropin) is used in endocrine and pediatric growth disorders to replace deficient growth hormone.

Growth hormone deficiency: restores normal growth velocity and metabolic function. Turner syndrome: promotes linear growth and improves height outcomes. Prader‑Willi syndrome: enhances growth and supports favorable body composition. Chronic renal insufficiency: aids growth in children with renal disease. Idiopathic short stature: increases height potential in children with unexplained growth delay. Small for gestational age (SGA) children: facilitates catch‑up growth.

Somatropin may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Injection site reactions: redness, swelling, or pain at the injection site. - Headache: mild to moderate headache. - Joint pain: arthralgia. - Edema: peripheral fluid retention.

Serious or Rare Side Effects: - Intracranial hypertension: signs of increased intracranial pressure. - Diabetes mellitus: hyperglycemia or new‑onset diabetes. - Allergic reactions: anaphylaxis, rash, or urticaria.

When prescribing somatropin, clinicians should consider several safety measures. - Dose titration: adjust based on IGF‑1 levels and growth response. - Monitoring: regular assessment of glucose, thyroid function, and intracranial pressure. - Contraindications: avoid in patients with active malignancy. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Pediatric monitoring: assess growth velocity and bone age regularly. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Somatropin can interact with other medicines, requiring attention to potential effects.

Major Interactions (Avoid): - Insulin or oral hypoglycemics: somatropin may worsen hyperglycemia; dose adjustment may be needed. - Glucocorticoids: may antagonize growth‑promoting effects; monitor IGF‑1 and growth response.

Moderate Interactions (Monitor Closely): - Thyroid hormone replacement: somatropin can increase conversion of T4 to T3; monitor thyroid tests. - Estrogen therapy: may enhance IGF‑1 response; adjust dosing as required. - Cyclosporine: may increase risk of fluid retention; observe for edema.